Two dual GPBAR1/FXR agonists, BAR502 and INT767, both prevent liver injury in preclinical experiments in NAFLD [189] (Figure 3). The gene discussed is GPBAR1; the disease is metabolic dysfunction-associated steatotic liver disease.